J.A. Lieberman

3.2k total citations · 1 hit paper
60 papers, 2.5k citations indexed

About

J.A. Lieberman is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, J.A. Lieberman has authored 60 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Psychiatry and Mental health, 10 papers in Pharmacology and 10 papers in Cognitive Neuroscience. Recurrent topics in J.A. Lieberman's work include Schizophrenia research and treatment (39 papers), Treatment of Major Depression (9 papers) and Functional Brain Connectivity Studies (8 papers). J.A. Lieberman is often cited by papers focused on Schizophrenia research and treatment (39 papers), Treatment of Major Depression (9 papers) and Functional Brain Connectivity Studies (8 papers). J.A. Lieberman collaborates with scholars based in United States, Japan and Czechia. J.A. Lieberman's co-authors include John M. Kane, Michael Borenstein, Simcha Pollack, S. Szymanski, Miranda Chakos, Celeste A. Johns, Robert M. Bilder, Allan Z. Safferman, Michael H. Kronig and Manzar Ashtari and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Pharmacological Reviews.

In The Last Decade

J.A. Lieberman

59 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs

1994 474 citations Miranda Chakos, J.A. Lieberman et al. American Journal of Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.A. Lieberman United States	21	1.9k	505	422	395	390	60	2.5k
Hélio Elkis Brazil	26	1.4k 0.7×	574 1.1×	270 0.6×	505 1.3×	162 0.4×	105	2.2k
Eduard Parellada Spain	30	1.4k 0.7×	478 0.9×	233 0.6×	322 0.8×	184 0.5×	98	2.5k
S.R. Marder United States	16	2.4k 1.3×	499 1.0×	821 1.9×	692 1.8×	174 0.4×	45	3.2k
Henrik Lublin Denmark	25	1.3k 0.7×	438 0.9×	214 0.5×	246 0.6×	166 0.4×	59	2.0k
S. Szymanski United States	19	2.0k 1.1×	338 0.7×	755 1.8×	746 1.9×	161 0.4×	37	2.6k
Arsime Demjaha United Kingdom	23	1.5k 0.8×	568 1.1×	425 1.0×	522 1.3×	95 0.2×	45	2.2k
Paul A. Thompson United States	20	969 0.5×	394 0.8×	248 0.6×	269 0.7×	85 0.2×	32	1.8k
EveC. Johnstone United Kingdom	7	1.1k 0.6×	493 1.0×	234 0.6×	185 0.5×	99 0.3×	10	1.7k
M.A. Reveley United Kingdom	20	878 0.5×	431 0.9×	138 0.3×	190 0.5×	155 0.4×	37	1.5k
Adam Wolkin United States	27	1.3k 0.7×	1.2k 2.3×	176 0.4×	166 0.4×	181 0.5×	42	2.6k

Countries citing papers authored by J.A. Lieberman

Since Specialization

Citations

This map shows the geographic impact of J.A. Lieberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.A. Lieberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.A. Lieberman more than expected).

Fields of papers citing papers by J.A. Lieberman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.A. Lieberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.A. Lieberman. The network helps show where J.A. Lieberman may publish in the future.

Co-authorship network of co-authors of J.A. Lieberman

This figure shows the co-authorship network connecting the top 25 collaborators of J.A. Lieberman. A scholar is included among the top collaborators of J.A. Lieberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.A. Lieberman. J.A. Lieberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lieberman, J.A., F.P. Bymaster, Herbert Y. Meltzer, et al.. (2008). Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection (Pharmacological Reviews (2002) 60, (358-403)). Pharmacological Reviews. 60(4). 18 indexed citations

McEvoy, Joseph P., Diana O. Perkins, Hongbin Gu, Robert M. Hamer, & J.A. Lieberman. (2006). P.3.c.054 Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment. European Neuropsychopharmacology. 16. S425–S426. 4 indexed citations

Renshaw, Perry F., et al.. (2003). Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis. Schizophrenia Research. 60(1). 301–301. 4 indexed citations

Centorrino, Franca, Robert M. Hamer, Mauricio Tohen, & J.A. Lieberman. (2003). Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia. Schizophrenia Research. 60(1). 277–277. 4 indexed citations

Kahn, René S., J.A. Lieberman, C. Charles, et al.. (2003). P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia. European Neuropsychopharmacology. 13. S337–S337. 1 indexed citations

Graham, Karen A., Diana O. Perkins, Joyce B. Harp, et al.. (2003). Investigation of olanzapine-associated weight gain in first episode subjects. Schizophrenia Research. 60(1). 355–356. 1 indexed citations

Levy, Deborah L., et al.. (2000). Quantitative characterization of eye tracking dysfunction in schizophrenia. Schizophrenia Research. 42(3). 171–185. 42 indexed citations

Lieberman, J.A.. (1995). Signs and Symptoms. Archives of General Psychiatry. 52(5). 361–361. 11 indexed citations

Woerner, Margaret G., et al.. (1995). Diagnostic stability in patients followed from their first episode of schizophrenia or schizoaffective disorder. Schizophrenia Research. 15(1-2). 24–24. 1 indexed citations

10.

Kane, John M., Allan Z. Safferman, Simcha Pollack, et al.. (1994). Clozapine, negative symptoms, and extrapyramidal side effects.. PubMed. 55 Suppl B. 74–7. 23 indexed citations

11.

Safferman, Allan Z., et al.. (1993). Predictors of response to clozapine in chronic schizophrenia. Schizophrenia Research. 9(2-3). 249–249. 1 indexed citations

12.

Woerner, Margaret G., Bruce L. Saltz, John M. Kane, J.A. Lieberman, & José Alvir. (1993). Diabetes and development of tardive dyskinesia. American Journal of Psychiatry. 150(6). 966–968. 55 indexed citations

13.

Lieberman, J.A.. (1993). Brain Morphology, Dopamine, and Eye-Tracking Abnormalities in First-Episode Schizophrenia. Archives of General Psychiatry. 50(5). 357–357. 83 indexed citations

14.

Lieberman, J.A. & José Alvir. (1992). A Report of Clozapine† - Induced Agranulocytosis in the United States. Drug Safety. 7(Supplement 1). 1–2. 36 indexed citations

15.

Lieberman, J.A., José Alvir, Margaret G. Woerner, et al.. (1992). Prospective Study of Psychobiology in First-episode Schizophrenia at Hillside Hospital. Schizophrenia Bulletin. 18(3). 351–371. 133 indexed citations

16.

Lieberman, J.A., David Mayerhoff, Antony Loebel, S. Geisler, & José Alvir. (1992). Evidence for sensitization in the early stage of schizophrenia. Schizophrenia Research. 6(2). 109–109. 1 indexed citations

17.

Mayerhoff, David, Antony Loebel, S. Geisler, et al.. (1992). The deficit state in a prospective study of first-episode schizophrenia. Schizophrenia Research. 6(2). 168–169. 3 indexed citations

18.

Szymanski, S., John M. Kane, & J.A. Lieberman. (1991). A Selective Review of Biological Markers in Schizophrenia. Schizophrenia Bulletin. 17(1). 99–111. 38 indexed citations

19.

Lieberman, J.A., Gustav Degreef, Manzar Ashtari, B. Bogerts, & José Alvir. (1991). Brain morphology in first episode schizophrenia. Schizophrenia Research. 4(3). 387–388. 1 indexed citations

20.

Lieberman, J.A.. (1990). HLA-B38, DR4, DQw3 and Clozapine-Induced Agranulocytosis in Jewish Patients With Schizophrenia. Archives of General Psychiatry. 47(10). 945–945. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact